Welcome to the NavRL repository! This repository provides the implementation of the NavRL framework, designed to enable robots to safely navigate dynamic environments using Reinforcement Learning.
Targeting oncogenic ROS1 fusion proteins with crizotinib has shown promising clinical outcomes in non-small cell lung cancer (NSCLC) patients, but emergence of resistance to therapy has been reported.
Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the phase II registrational Komet-001 trial in patients with relapsed/refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback